UNSPSC 51173214: Bisacodyl/tannic acid

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RS300. This VA Drug Class (RS300) classifies this compound as belonging to the group LAXATIVES, RECTAL.

UNSPSC 51173214 Bisacodyl/tannic acid is a Commodity code that encompasses pharmaceutical products, including laxative agents and related medications, that state and local governments procure for correctional health programs, community supervision facilities, and public health benefit plans. Recent solicitations show state and local buyers acquiring these products primarily through two channels: direct procurement for correctional and offender-supervision programs where bowel-management and health-screening protocols require specific pharmaceutical inventory, and participation in cooperative purchasing alliances that aggregate demand across multiple state agencies and jurisdictions to secure generic pharmaceuticals and over-the-counter products at volume pricing. The scope includes not only the active pharmaceutical ingredient but also formulated products meeting cGMP and FDA requirements, with vendors required to maintain supply-chain security certification (DSCSA compliance), manage NDC-specific inventory, and provide pricing across multiple net-price and WAC-based models.

Recent activity centers on Texas and Minnesota, with Collin County Community Supervision and Corrections Department (Texas) issuing RFP 2026-327 for offender specimen collection and drug testing services closing July 23, 2026 (estimated contract value $600,000 for two years with renewal options), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline serving multiple state and local participants across Minnesota and Oregon. The Texas Health and Human Services Commission has also posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling emerging procurement interest in alternative supply-chain models. The mix of issuing bodies—state health agencies, county corrections departments, and state-led cooperative purchasing consortia—indicates that bisacodyl and related pharmaceutical agents move through correctional health, public benefit programs, and bulk cooperative channels rather than through individual municipality procurement.